Patent application number | Description | Published |
20090104677 | Heteroaromatic Selective Inhibitors of Neuronal Nitric Oxide Synthase - Compounds inhibiting neuronal nitric oxide synthase (nNOS) for potential treatment in neurodegenerative diseases, such as stroke, Alzheimer's disease, Parkinson's disease, Huntington's disease, such compounds of a formula. | 04-23-2009 |
20100190230 | Potent and Selective Neuronal Nitric Oxide Synthase Inhibitors with Improved Membrane Permeability - Compounds and related compositions and methods as can be used to inhibit neuronal nitric oxide synthase and as can be employed in the treatment of various neurodegenerative diseases. | 07-29-2010 |
20100203613 | Aminopyridine Dimer Compounds, Compositions and Related Methods for Neuronal Nitric Oxide Synthase Inhibition - Nitric oxide synthase (NOS) inhibitor compounds comprising bi-terminal aromatic ring moieties, and related methods of NOS inhibition. | 08-12-2010 |
20100204088 | Cyclic Peptide Antitumor Agents - Cyclic peptide compounds and derivatives thereof having antitumor activity as shown by treatment of human melanoma, pancreatic, breast, prostate cancer cells. | 08-12-2010 |
20100292484 | Chiral Pyrrolidine Core Compounds en route to Inhibitors of Nitric Oxide Synthase - Diastereomeric pyrrolidine compounds and methods of preparation, as can be used en route to the preparation of a range of nitric oxide synthase inhibitors. | 11-18-2010 |
20110178043 | Inhibitors of the mevalonate pathway of streptococcus pneumoniae - Compounds and related methods as can be used for selective mevalonate pathway inhibitors. | 07-21-2011 |
20110237907 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS - The present invention relates to the identification of compounds and pharmaceutical compositions thereof for treating subjects with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The invention also provides methods of preparing the provided compounds. | 09-29-2011 |
20120004415 | Chiral Synthesis of Pyrrolidine Core Compounds en route to Neuronal Nitric Oxide Synthase Inhibitors - A chiral synthesis of pyrrolidine compounds en route to selective neuronal nitric oxide synthase inhibitors, and representative inhibitor compounds heretofore unattainable. | 01-05-2012 |
20120046309 | PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS - The present invention relates to the identification of inventive pyrimidine-2,4,6-triones (PYT compounds) and pharmaceutical compositions thereof for treating subjects with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The invention also provides methods of preparing the inventive PYT compounds. | 02-23-2012 |
20120088798 | Intramolecular Hydrogen-Bonded Nitric Oxide Synthase Inhibitors - Compounds and related compositions and methods as can be used to selectively inhibit neuronal nitric oxide synthase and as can be employed in the treatment of various neurodegenerative diseases. | 04-12-2012 |
20120122799 | CYCLIC PEPTIDE ANTITUMOR AGENTS - Cyclic peptide compounds and derivatives thereof having antitumor activity as shown by treatment of human melanoma, pancreatic, breast, prostate cancer cells. | 05-17-2012 |
20120196883 | SELECTIVE CALCIUM CHANNEL ANTAGONISTS - The present invention relates to compositions and methods for the treatment and/or prevention of neurodegenerative disorders, e.g., Parkinson's disease (PD). In particular, the present invention provides compositions comprising selective antagonists of calcium ion channels (e.g., cav1.3-type ion channels), and methods of use thereof to treat or prevent neurodegenerative disorders. | 08-02-2012 |
20120238016 | Specific nNOS Inhibitors for the Therapy And Prevention Of Human Melanoma - Methods for melanoma treatment and prevention with selective nitric oxide synthase inhibitor compounds and related pharmaceutical compositions, alone or in conjunction with one or more other melanoma therapies. | 09-20-2012 |
20120245380 | Inhibition of Ornithine Aminotransferase for the Treatment of Proliferative Disorders - The invention relates to inhibition of ornithine aminotransferase (OAT) for suppression of tumor cells proliferation. More particularly, the invention relates to methods of treatment of proliferative disorders by the selective inhibition of OAT, and further provides the use of OAT inhibitors, specifically, 5-amino-1,3-hexadienyl-carboxylic acid (Gabaculine), and Gabaculine analogue 8, for compositions and methods for the treatment of proliferative disorders such as hepatocellular carcinoma. The invention further provides methods and kits for the diagnosis of a pathologic proliferative disorder in a mammalian subject, based on determining the level of OAT expressed in a biological sample obtained from a subject. | 09-27-2012 |
20120258513 | Selective Neuronal Nitric Oxide Synthase Inhibitors - Compounds and related methods for selective inhibition of neuronal nitric oxide synthase over inducible and endothelial isoforms, such compounds as can provide reduced cationic character and enhanced bioavailability. | 10-11-2012 |
20120264765 | Cyclohexane-1,3-Diones for Use in the Treatment of Amyotrophic Lateral Sclerosis - The present invention relates to the identification of provided cyclohexane-1,3-diones (CHD compounds) and pharmaceutical compositions thereof for treating subjects with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The invention also provides methods of preparing the provided CHD compounds. | 10-18-2012 |
20130040359 | Aminopyridine dimer compounds, compositions and related methods for neuronal nitric oxide synthase inhibition - Nitric oxide synthase (NOS) inhibitor compounds comprising bi-terminal aromatic ring moieties, and related methods of NOS inhibition. | 02-14-2013 |
20130041028 | METHODS OF USING (1S,3S)-3-AMINO-4-DIFLUOROMETHYLENYL-1-CYCLOPENTANOIC ACID - (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid also known as CPP-115 or its pharmaceutically acceptable salts can be used to treat addiction and neurological disorders such as epilepsy without side effects such as visual field defects caused by vigabatrin (Sabril). | 02-14-2013 |